Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
Authors:
- Rita S. MehtaRMRita S. Mehta
- Robert A. BurgerRBRobert A. Burger
- Ing-Ru YuIYIng-Ru Yu
- Ainura S. KyshtoobayevaAKAinura S. Kyshtoobayeva
- Bradley J. MonkBMBradley J. Monk
- Alberto ManettaAMAlberto Manetta
- Michael L. BermanMBMichael L. Berman
- Philip J. DisaiaPDPhilip J. Disaia
- John P. FruehaufJFJohn P. Fruehauf
Open Access
- 1 September 2005
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 98 (3) , 360-368
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Association between in Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer PatientsGynecologic Oncology, 2002
- Recent Advancements in the Treatment of Epithelial Ovarian Cancer*Journal of Obstetrics and Gynaecology Research, 2001
- Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance AssayBreast Cancer Research and Treatment, 2001
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With CancerJournal of Clinical Oncology, 1999
- The Clinical Relevance of Chemosensitivity Testing in Ovarian CancerCancer Detection Prevention, 1998
- Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Clonal Origin of Epithelial Ovarian Carcinoma: Analysis by Loss of Heterozygosity, p53 Mutation, and X-Chromosome InactivationJNCI: Journal of the National Cancer Institute, 1992